NVS Novartis Corporation: Prakiraan wutah bathi resik saben saham kanggo taun ngarep

Analyst 12-month EPS growth targets reflect market expectations, where 11.20 serves as the target level. Novartis AG (NVS) is betting on oncology developments and generous shareholder payouts. The transformation into a pure-play innovation structure via radioligand therapy is driving growth. The portfolio is based on targeted treatments for complex pathologies, excluding low-margin generics.

When screening issuer reliability, this indicator serves as a filter for fundamental stability. It measures the percentage change in expected earnings per share (EPS) for the following year, separating the long-term trend from short-term market noise. For Novartis AG (NVS), the stability of these forecasts confirms the efficiency of complex international cold chain logistics and the preservation of high-cost medications. By analyzing the current vector of next year's EPS forecasts, an investor assesses the risk of correction in the event of sharp valuation revisions.